 In the patients who were being hospitalized with COVID-related pneumonia, they were randomized to either receive Paxlovid or not. The patient's mortality rates were compared after 28 days. There was absolutely no difference. No difference. So, yeah. Suggestion that Paxlovid may have some value for maybe the people who are most immunosuppressed. Those people, though, may be...